New hope for Tough-to-Treat leukemias: experimental combo enters human testing
Disease control
Recruiting now
This early-stage study is testing the safety and best dose of a new drug, ABL001, when combined with three existing leukemia medications. It is for adults with two specific, aggressive types of blood cancer (BCR-ABL+ B-ALL or CML in blast crisis). The main goal is to see if this …
Phase: PHASE1 • Sponsor: Marlise Luskin, MD • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC